Skip to main content

Global Navigation

  • Other sites:
  • ECDC
  • European Antibiotic Awareness Day
  • ESCAIDE - Scientific conference
  • Eurosurveillance journal
  • EVIP - Vaccination portal
European Centre for Disease Prevention and Control

European Centre for Disease Prevention and Control

An agency of the European Union

Main Navigation

  • Home
  • All topics: A to Z

Secondary Navigation

  • Newsroom
  • Publications & data
  • Tools
  • About us

Search

Filter by:
Page 1 of 7 // 62 Results found

News

COVID-19: Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines

News - 6 Apr 2022

EMA and ECDC have reviewed currently available studies and epidemiological data to provide a common position for EU/EEA countries on the current need and potential benefit of a fourth dose (second booster dose) of mRNA COVID-19 vaccines.

  • Coronavirus
  • COVID-19
  • EU/EEA
  • Immunisation
  • Public health threat
  • Scientific advice
  • Vaccine effectiveness

Publication

Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 30 years and older, ECDC multi-country study – second update

Technical report - 14 Mar 2022

This second update contains vaccine effectiveness results among individuals aged 30 years and older, for the pre-Delta and the Delta-dominant periods (3 January–31 May 2021 and 1 July–15 December 2021, respectively).

Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 30 years and older, ECDC multi-country study – second update - EN - [PDF-922.09 KB]
  • Coronavirus
  • COVID-19
  • Immunisation
  • Public health threat
  • Respiratory diseases
  • SARS-CoV-2 variants
  • Vaccine effectiveness

Publication

COVID-19 vaccine effectiveness in adolescents aged 12–17 years and interim public health considerations for administration of a booster dose

Technical report - 8 Feb 2022

The purpose of this document is to review the evidence of COVID-19 vaccine effectiveness and duration of immunity following vaccination in adolescents aged 12-17 years, and to outline interim public health considerations for the potential use of a booster dose in this group.

COVID-19 vaccine effectiveness in adolescents aged 12–17 years and interim public health considerations for administration of a booster dose - EN - [PDF-604.25 KB]
  • Coronavirus
  • COVID-19
  • Immunisation
  • Public health threat
  • Vaccine effectiveness

Event

Flu Awareness Campaign 2021

Campaign

The Flu Awareness Campaign is marked across the WHO European Region every year in October. It aims to raise awareness of the importance of vaccination for people’s health and well-being and to increase the uptake of seasonal influenza vaccination of people with underlying risk factors.

  • Immunisation
  • Influenza in humans, seasonal
  • Vaccination coverage
  • Vaccine effectiveness
  • Vaccine efficacy
  • Vaccine hesitancy

News

Early influenza cases indicate the possibility of severe upcoming season for elderly

Press release - 26 Oct 2021

Although the overall number of influenza detections in the majority of EU/EEA countries is still low, indications show that influenza circulation is above the seasonal threshold in Croatia, which is unusually early. The main reported subtype among the cases recorded in EU/EEA during the past month is A(H3N2), which disproportionally affects older people, and is associated with lower vaccine effectiveness. This is a sign that the upcoming influenza season could be severe for elderly people, and that influenza patterns may vary between countries in terms of timing.

  • EU/EEA
  • Immunisation
  • Influenza
  • Influenza in humans, seasonal
  • Vaccination coverage
  • Vaccine effectiveness

Publication

Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratory-confirmed with SARS-CoV-2, version 1.0

Technical report - 8 Oct 2021

Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratory-confirmed with SARS-CoV-2, version 1.0.

Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratory-confirmed with SARS-CoV-2, version 1.0 - EN - [PDF-1.16 MB]
  • Coronavirus
  • COVID-19
  • Immunisation
  • Public health threat
  • Vaccine effectiveness

News

ECDC builds study infrastructure to monitor COVID-19 vaccine effectiveness

News story - 8 Oct 2021

ECDC is creating new infrastructure to allow for regular monitoring and analysis of COVID-19 vaccine effectiveness (VE) over time, using a multi-country approach, through the implementation of studies in different settings.

  • Coronavirus
  • COVID-19
  • Immunisation
  • Public health threat
  • Vaccine effectiveness

Event

Flu Awareness Week, 5-9 October 2020

Campaign
5 Oct 2020 - 9 Oct 2020
World Health Organization (WHO) - Regional office for Europe

The Flu Awareness Week is marked across the WHO European Region every year in October. It aims to raise awareness of the importance of vaccination for people’s health and well-being and to increase the uptake of seasonal influenza vaccination of people with underlying risk factors.

  • Immunisation
  • Influenza in humans, seasonal
  • Vaccination coverage
  • Vaccine effectiveness
  • Vaccine efficacy
  • Vaccine hesitancy

Predominance of influenza virus A(H3N2) 3C.2a1b and A(H1N1)pdm09 6B.1A5A genetic subclades in the WHO European Region, 2018–2019

Peer-Reviewed Publication

Jul 2020 - Vaccine - 38(35):5707-5717

Melidou, A., Hungnes, O., Pereyaslov, D., Adlhoch, C., Segaloff, H., Robesyn, E., Penttinen, P., Olsen, S.J.

  • Avian influenza virus
  • Europe
  • Influenza
  • Influenza A (H1N1)
  • Influenza in humans, avian origin
  • Laboratories
  • Surveillance
  • Vaccine effectiveness
  • Zoonotic influenza

Data

Evidence of the efficacy of the HPV vaccines in males

Data set - 30 Mar 2020

Efficacy/effectiveness, immunogenicity, safety and tolerability of HPV vaccines in males

  • Human papillomavirus infection
  • Immunisation
  • Vaccine effectiveness

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Next page ››
  • Last page Last »
  • About us

    • What we do
    • Who we are
    • Governance
  • Work with us

    • Vacancies
    • Fellowships
    • Traineeships
    • Procurement and grants
  • Contact ECDC

    • Visit us
    • ECDC press room
    • Social media
Log in to ECDC Extranet
Newsletter RSS

Follow us:

Facebook Twitter Youtube Linked In Vimeo Slide share

Footer Navigation

  • Legal notice
  • Copyright
  • Access to TESSy
  • Personal data protection
  • Language policy
  • Cookies
  • Accessibility
  • Sitemap
© European Centre for Disease Prevention and Control (ECDC) 2022
  • Other sites:
    • ECDC
    • European Antibiotic Awareness Day
    • ESCAIDE - Scientific conference
    • Eurosurveillance journal
    • EVIP - Vaccination portal
  • Search:
  • Home
  • All topics: A to Z
  • Newsroom
  • Publications & data
  • Tools
  • About us